Navigation Links
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Date:6/1/2009

at taribavirin could replace ribavirin as a cornerstone in the treatment of hepatitis C, but with the advantage of less anemia," said J. Michael Pearson, chairman and chief executive officer. "These encouraging results, coupled with Schering-Plough's option agreement for a license in Japan, could offer new alternatives for patients suffering from this disease and we will continue to pursue additional licensing and partnering opportunities in order to maximize this compound's potential."

The most common adverse events during treatment were fatigue, nausea, flu-like symptoms, headache and diarrhea. The incidence rates for these adverse events among treatment arms were generally comparable except with respect to diarrhea, where incidence of diarrhea was approximately twice as common in patients receiving taribavirin compared to patients receiving ribavirin. However, the diarrhea was generally mild and not treatment limiting for taribavirin or ribavirin patients.

About Taribavirin

Taribavirin is an investigational compound that has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigation, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until approved for marketing by the FDA. Similar restrictions apply in other countries.

About Study 204

The Phase IIb trial is a U.S. multi-center, randomized, parallel, open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at weight-based doses of 20 mg/kg, 25 mg/kg, and 30 mg/kg per day in combination with pegylated interferon alfa-2b. The control group was administered weight-based dose ribavirin (800/1000/1200/1400mg daily) and pegylated interferon alfa-2b. Overall treatment duration is 48 weeks with a post-treatment follow-up period of 24 weeks.

In the Phase I
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... MIAMI BEACH, Fla. , May 28, 2015 /PRNewswire/ ... data supporting the anti-cancer potential of its growth hormone-releasing ... presentation at the 2015 ASCO Annual Meeting. The ... the target for Biscayne,s anti-cancer GHRH blockers, is present ... receptor status. These findings suggest that GHRH antagonists could ...
(Date:5/28/2015)... York, NY (PRWEB) May 28, 2015 ... renewed and enhanced its long term partnership with PTI ... work together to provide clients with custom-tailored method ... the art instruments currently available. The agreement includes a ... companies’ employees across organizational lines. This enables a ...
(Date:5/28/2015)... Clinerion, an eClinical technology ... the Alliance for Clinical Research Excellence and ... operating in the public interest and dedicated ... quality, safety, integrity and operational effectiveness in ... pleased to announce their partnership for accelerating ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 The Academy of ... join in celebrating National Model Aviation Day. The third annual ... was created to celebrate the model aviation hobby nation-wide and ... all of its approximately 2,350 chartered clubs to celebrate the ... event in their communities. There will also be a local ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3
... aid the fight of the deadly outbreak of E. ... at the University Medical Centre Hamburg-Eppendorf have released an ... data previously released and submitted to NCBI in the ... assembled using the latest ion semiconductor sequencing technology, there ...
...  Grifols, S.A. (NASDAQ: GRFS ) ... based in Barcelona, Spain today announced that on ... Talecris Biotherapeutics Holdings Corp. ("Talecris").  In partial consideration ... shares that trade in the U.S. as Grifols ...
... LifeVantage Corporation (OTCBB: LFVN), the maker ... the reduction of oxidative stress by the synergistic ... peer-reviewed review article involving Protandim® was published in ... (Logo:   http://photos.prnewswire.com/prnh/20090930/LIFEVANTAGELOGO ) ...
Cached Biology Technology:Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3Grifols Announces the Completion of its Acquisition of Talecris and the Listing of its ADSs on NASDAQ 2LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 2LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 3LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 4LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 5
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... HOLE, MADr. Bruce J. Peterson, a senior scholar at ... the Association for the Sciences of Limnology and Oceanography ... Achievement Award. The award honors the career achievements of ... importance and long-term influence. Dr. Peterson is being honored ...
... breakthrough at the University of Huddersfield has received extra stimulus ... major conference in Australia. Mari L. Uchimoto, from Montana, ... member of its Forensic Genetics Research Group and supervised by ... a team working on the use of microRNA analysis in ...
... the Norwegian University of Science and Technology in Trondheim have ... of winter conditions for fish in streams and rivers in ... journal BioScience . It is well known that ... in streams and rivers. It is reasonable to assume that ...
Cached Biology News:MBL scientist Bruce Peterson wins ASLO Lifetime Achievement Award 2MBL scientist Bruce Peterson wins ASLO Lifetime Achievement Award 3Mari's presentation tops ANZFSS International Symposium 2Extreme winters impact fish negatively 2